IntroductionThe aim of this practice guideline was to develop evidence-based recommendations for screening high-risk populations for lung cancer.MethodsThe guideline was developed using the methods of Cancer Care Ontario's Program in Evidence-Based Care. The core methodology of the Program in Evidence-Based Care's guideline development process is systematic review. A systematic review had recently been completed by a collaboration of the American Cancer Society, the American College of Chest Physicians, the American Society of Clinical Oncology, and the National Comprehensive Cancer Network. The evidence from that systematic review formed the basis of the recommendations, which were reviewed, and amended where necessary, by clinical experts...
Lung cancer is the most frequently fatal cancer, with poor survival once the disease is advanced. An...
The purpose of this systematic review was to provide physicians and patients with a synthesis of the...
Lung cancer kills more people than any other cancer in the UK (5-year survival < 13%). Early diagnos...
IntroductionThe aim of this practice guideline was to develop evidence-based recommendations for scr...
Findings from the National Cancer Institute's National Lung Screening Trial established that lung ca...
Screening for lung cancer is not currently recommended, even in persons at high risk for this condit...
ObjectivesLung cancer is the leading cause of death among all cancers. An estimated 29% of the globa...
The lethality of lung cancer is related to the advanced stage at diagnosis. Initial studies have dem...
Background: Lung cancer typically exhibits symptoms only after the disease has spread, making cure u...
Background: Lung cancer is a substantial public health problem in western countries. Previous studie...
Lung cancer screening by low-dose chest CT (LDCT) is now being implemented in the United States, and...
ContextLung cancer is the leading cause of cancer death. Most patients are diagnosed with advanced d...
Lung cancer still has a big proportion of cancer related deaths inspite of improvements in chemother...
Background: Diagnosis of lung cancer frequently occurs in its later stages. Low-dose computed tomogr...
In the past decade, the introduction of molecularly targeted agents and immune-checkpoint inhibitors...
Lung cancer is the most frequently fatal cancer, with poor survival once the disease is advanced. An...
The purpose of this systematic review was to provide physicians and patients with a synthesis of the...
Lung cancer kills more people than any other cancer in the UK (5-year survival < 13%). Early diagnos...
IntroductionThe aim of this practice guideline was to develop evidence-based recommendations for scr...
Findings from the National Cancer Institute's National Lung Screening Trial established that lung ca...
Screening for lung cancer is not currently recommended, even in persons at high risk for this condit...
ObjectivesLung cancer is the leading cause of death among all cancers. An estimated 29% of the globa...
The lethality of lung cancer is related to the advanced stage at diagnosis. Initial studies have dem...
Background: Lung cancer typically exhibits symptoms only after the disease has spread, making cure u...
Background: Lung cancer is a substantial public health problem in western countries. Previous studie...
Lung cancer screening by low-dose chest CT (LDCT) is now being implemented in the United States, and...
ContextLung cancer is the leading cause of cancer death. Most patients are diagnosed with advanced d...
Lung cancer still has a big proportion of cancer related deaths inspite of improvements in chemother...
Background: Diagnosis of lung cancer frequently occurs in its later stages. Low-dose computed tomogr...
In the past decade, the introduction of molecularly targeted agents and immune-checkpoint inhibitors...
Lung cancer is the most frequently fatal cancer, with poor survival once the disease is advanced. An...
The purpose of this systematic review was to provide physicians and patients with a synthesis of the...
Lung cancer kills more people than any other cancer in the UK (5-year survival < 13%). Early diagnos...